Phase II/III clinical trial of L-105 in patients with hepatic encephalopathy

Trial Profile

Phase II/III clinical trial of L-105 in patients with hepatic encephalopathy

Completed
Phase of Trial: Phase II/III

Latest Information Update: 14 Dec 2016

At a glance

  • Drugs Rifaximin (Primary) ; Lactitol
  • Indications Hepatic encephalopathy; Hyperammonaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors ASKA Pharmaceutical
  • Most Recent Events

    • 02 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top